End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
994 KRW | +8.52% | -.--% | -80.70% |
Mar. 29 | CANARIABIO Inc.(KOSDAQ:A016790) dropped from S&P Global BMI Index | CI |
Jan. 24 | Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis | MT |
Sales 2022 | 158B 117M | Sales 2023 | 161B 119M | Capitalization | 927B 685M |
---|---|---|---|---|---|
Net income 2022 | -283B -209M | Net income 2023 | -208B -154M | EV / Sales 2022 | 4.42 x |
Net Debt 2022 | 118B 86.86M | Net Debt 2023 | 106B 78.37M | EV / Sales 2023 | 6.43 x |
P/E ratio 2022 |
-1.62
x | P/E ratio 2023 |
-3.87
x | Employees | 78 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.53% |
1 day | +8.52% | ||
3 months | -28.08% | ||
6 months | -82.03% | ||
Current year | -80.70% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - |
1st Jan change | Capi. | |
---|---|---|
-80.70% | 138M | |
+16.77% | 12.05B | |
+3.11% | 5.94B | |
+6.97% | 5.51B | |
+14.80% | 5.03B | |
-20.47% | 2.7B | |
+4.52% | 1.95B | |
-14.27% | 1.25B | |
-10.16% | 952M | |
-18.21% | 919M |
- Stock Market
- Equities
- A016790 Stock